Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JS 212

Next Previous
Drug Profile

JS 212

Alternative Names: JS-212

Latest Information Update: 30 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Junshi Biosciences
  • Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Lung cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours

Most Recent Events

  • 13 Jul 2026 Shanghai Junshi Bioscience plans a phase clinical trial for Non small cell lung cancer (Late stage disease, Metastatic disease, First line therapy, Combination therapy) in China (IV, Infusion) in July 2026 (NCT07714304)
  • 24 Apr 2026 Phase-II clinical trials in Colorectal cancer (Combination therapy, Metastatic disease, Late-stage disease, First-line therapy) in China (Parenteral)(NCT07503756)
  • 23 Apr 2026 Phase-II clinical trials in Solid tumours (Monotherapy, Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease, Late-stage disease) in China (IV)(NCT07480733)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top